Zobrazeno 1 - 10
of 1 203
pro vyhledávání: '"Lacabaratz, C."'
Autor:
Wiedemann A; Vaccine Research Institute, Université Paris-Est, Créteil, France.; INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy, Créteil, France., Lhomme E; Vaccine Research Institute, Université Paris-Est, Créteil, France.; Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, Bordeaux, France.; Univ. Bordeaux, Inserm, Population Health Research Center, UMR 1219, INRIA SISTM, Bordeaux, France., Huchon M; Vaccine Research Institute, Université Paris-Est, Créteil, France.; Univ. Bordeaux, Inserm, Population Health Research Center, UMR 1219, INRIA SISTM, Bordeaux, France., Foucat E; Vaccine Research Institute, Université Paris-Est, Créteil, France.; INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy, Créteil, France., Bérerd-Camara M; Alliance for International Medical Action, Dakar, Senegal., Guillaumat L; Vaccine Research Institute, Université Paris-Est, Créteil, France.; INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy, Créteil, France., Yaradouno M; Alliance for International Medical Action, Dakar, Senegal., Tambalou J; Alliance for International Medical Action, Dakar, Senegal., Rodrigues C; Vaccine Research Institute, Université Paris-Est, Créteil, France.; INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy, Créteil, France., Ribeiro A; Vaccine Research Institute, Université Paris-Est, Créteil, France.; INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy, Créteil, France., Béavogui AH; Centre National de Formation et de Recherche en Santé Rurale (CNFRSR), Maferinyah, Guinea., Lacabaratz C; Vaccine Research Institute, Université Paris-Est, Créteil, France.; INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy, Créteil, France., Thiébaut R; Vaccine Research Institute, Université Paris-Est, Créteil, France.; Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, Bordeaux, France.; Univ. Bordeaux, Inserm, Population Health Research Center, UMR 1219, INRIA SISTM, Bordeaux, France., Richert L; Vaccine Research Institute, Université Paris-Est, Créteil, France.; Univ. Bordeaux, INSERM, Institut Bergonié, CHU de Bordeaux, CIC-EC 1401, Euclid/F-CRIN clinical trials platform, Bordeaux, France.; Univ. Bordeaux, Inserm, Population Health Research Center, UMR 1219, INRIA SISTM, Bordeaux, France., Lévy Y; Vaccine Research Institute, Université Paris-Est, Créteil, France. yves.levy@aphp.fr.; INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy, Créteil, France. yves.levy@aphp.fr.; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France. yves.levy@aphp.fr.
Publikováno v:
Nature communications [Nat Commun] 2024 Sep 03; Vol. 15 (1), pp. 7666. Date of Electronic Publication: 2024 Sep 03.
Autor:
Lacabaratz C; Vaccine Research Institute-VRI, France.; INSERM Unité U955, IMRB, Créteil, France.; Université Paris-Est, Faculté de Médecine, Créteil, France., Durand M; Vaccine Research Institute-VRI, France.; Univ. Bordeaux, Inserm, Population Health Research Center, UMR 1219, INRIA SISTM, Bordeaux, France., Wiedemann A; Vaccine Research Institute-VRI, France.; INSERM Unité U955, IMRB, Créteil, France.; Université Paris-Est, Faculté de Médecine, Créteil, France., Foucat E; Vaccine Research Institute-VRI, France.; INSERM Unité U955, IMRB, Créteil, France.; Université Paris-Est, Faculté de Médecine, Créteil, France., Surénaud M; Vaccine Research Institute-VRI, France.; INSERM Unité U955, IMRB, Créteil, France.; Université Paris-Est, Faculté de Médecine, Créteil, France., Krief C; Vaccine Research Institute-VRI, France.; INSERM Unité U955, IMRB, Créteil, France.; Université Paris-Est, Faculté de Médecine, Créteil, France., Guillaumat L; Vaccine Research Institute-VRI, France.; INSERM Unité U955, IMRB, Créteil, France.; Université Paris-Est, Faculté de Médecine, Créteil, France., Robinson C; Janssen Vaccines and Prevention, Leiden, The Netherlands., Luhn K; Janssen Vaccines and Prevention, Leiden, The Netherlands., Bockstal V; Janssen Vaccines and Prevention, Leiden, The Netherlands., Thiébaut R; Vaccine Research Institute-VRI, France.; Univ. Bordeaux, Inserm, Population Health Research Center, UMR 1219, INRIA SISTM, Bordeaux, France.; CHU Bordeaux, Department of medical information and CIC-EC 1401/Euclid F-CRIN, Bordeaux, France., Richert L; Vaccine Research Institute-VRI, France.; Univ. Bordeaux, Inserm, Population Health Research Center, UMR 1219, INRIA SISTM, Bordeaux, France.; CHU Bordeaux, Department of medical information and CIC-EC 1401/Euclid F-CRIN, Bordeaux, France., Lévy Y; Vaccine Research Institute-VRI, France.; INSERM Unité U955, IMRB, Créteil, France.; Université Paris-Est, Faculté de Médecine, Créteil, France.; Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Henri-Mondor Albert-Chenevier, service d'immunologie clinique, Créteil, France.
Publikováno v:
The Journal of infectious diseases [J Infect Dis] 2024 Jul 16. Date of Electronic Publication: 2024 Jul 16.
Autor:
Barry H; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso, Burkina Faso.; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team, Bordeaux, France., Lhomme E; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team, Bordeaux, France.; CHU Bordeaux, Department of Medical Information, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France., Surénaud M; Vaccine Research Institute (VRI), Créteil, France.; Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France., Nouctara M; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso, Burkina Faso., Robinson C; Janssen Vaccines & Prevention B.V., Leiden, Netherlands., Bockstal V; Janssen Vaccines & Prevention B.V., Leiden, Netherlands., Valea I; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso, Burkina Faso.; Institut de Recherche en Sciences de la Santé/Unité de Recherche Clinique de Nanoro, Burkina Faso., Somda S; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso, Burkina Faso.; Université Nazi BONI, UFR Sciences Exactes et Appliquées, Bobo-Dioulasso, Burkina Faso., Tinto H; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso, Burkina Faso.; Institut de Recherche en Sciences de la Santé/Unité de Recherche Clinique de Nanoro, Burkina Faso., Meda N; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso, Burkina Faso.; UFR Sciences de la santé, Université joseph Ki Zerbo, Ouagadougou, Burkina Faso., Greenwood B; London School of Hygiene & Tropical Medicine (LSHTM), London, United Kingdom., Thiébaut R; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team, Bordeaux, France.; CHU Bordeaux, Department of Medical Information, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France., Lacabaratz C; Vaccine Research Institute (VRI), Créteil, France.; Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France.
Publikováno v:
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2024 Apr 11; Vol. 18 (4), pp. e0011500. Date of Electronic Publication: 2024 Apr 11 (Print Publication: 2024).
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Colson, P., Ravaux, I., Tamalet, C., Glazunova, O., Baptiste, E., Chabriere, E., Wiedemann, A., Lacabaratz, C., Chefrour, M., Picard, C., Stein, A., Levy, Y., Raoult, D.
Publikováno v:
In Clinical Microbiology and Infection December 2014 20(12):1280-1288
Autor:
Barry, H, Mutua, G, Kibuuka, H, Anywaine, Z, Sirima, SB, Meda, N, Anzala, O, Eholie, S, Bétard, C, Richert, L, Lacabaratz, C, McElrath, MJ, de Rosa, S, Cohen, KW, Shukarev, G, Robinson, C, Gaddah, A, Heerwegh, D, Bockstal, V, Luhn, K, Leyssen, M, Douoguih, M, Thiébaut, R, Thiebaut, R
Publikováno v:
PLoS Medicine, Vol 18, Iss 10 (2021)
PLoS Medicine, Vol 18, Iss 10, p e1003813 (2021)
PLoS Medicine, Vol 18, Iss 10, p e1003813 (2021)
Background We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. Methods and findings In this randomised,
Autor:
Melica G; Clinical Immunology and Infectious Diseases Unit, Henri Mondor Hospital, APHP, Creteil, France.; Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France., Bartolucci P; Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France., Audureau E; Public Health Department, Henri Mondor Hospital, APHP, Mondor Institut of Biomedical Research Inserm U955, University Paris Est Creteil, Creteil, France., Le Corvoisier P; Clinical Investigation Center 1430, Inserm, Henri Mondor Hospital, APHP, Creteil, France., Habibi A; Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France., Gellen J; Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France., Selmane D; Public Health Department, Henri Mondor Hospital, APHP, Mondor Institut of Biomedical Research Inserm U955, University Paris Est Creteil, Creteil, France., Michel M; Internal Medicine Unit, Henri Mondor Hospital, APHP, Creteil, France., Lacabaratz C; Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France., Levy Y; Clinical Immunology and Infectious Diseases Unit, Henri Mondor Hospital, APHP, Creteil, France.; Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France.
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Jun 08; Vol. 76 (11), pp. 1949-1958.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Background: To address the unmet medical need for an effective prophylactic vaccine against Ebola virus we assessed the safety and immunogenicity of three different two-dose heterologous vaccination regimens with a replication-deficient adenovirus ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::7995bbe59e655da2955dbc3e0622b958
https://ora.ox.ac.uk/objects/uuid:65c7fab9-dfc7-49ae-90d5-259c0c8ce7ab
https://ora.ox.ac.uk/objects/uuid:65c7fab9-dfc7-49ae-90d5-259c0c8ce7ab
Autor:
WIEDEMANN, A., FOUCAT, E., Hocini, H., Lefebvre, C., Hejblum, Boris P., DURAND, Melany, KRUGER, Miriam, KEITA, A. K., Ayouba, A., MÉLY, S., FERNANDEZ, J. C., Touré, A., Fourati, S., LÉVY-MARCHAL, C., Raoul, H., Delaporte, E., Koivogui, L., THIEBAUT, Rodolphe, Lacabaratz, C., Levy, Y.
Publikováno v:
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.3730
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.3730
Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18–25]) after dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1398::99503b8ac5a3090bd9b022d37dfb73b0
https://hal.archives-ouvertes.fr/hal-03160838
https://hal.archives-ouvertes.fr/hal-03160838